The purpose and effect of this rule amendment is to update the rule to reflect the new position statement by the National Association of School Nurses incorporated by reference rule 6A-6.0253, FAC.  

  •  

    DEPARTMENT OF EDUCATION

    State Board of Education

    RULE NO.:RULE TITLE:

    6A-6.0252Use of Prescribed Pancreatic Enzyme Supplements

    PURPOSE AND EFFECT: The purpose and effect of this rule amendment is to update the rule to reflect the new position statement by the National Association of School Nurses incorporated by reference Rule 6A-6.0253, F.A.C.

    SUMMARY: The rule is amended because the National Association of School Nurses Position Statement was updated in June 2013. This rule was developed in cooperation with the Florida Department of Health (FDOH) to address self-administration of pancreatic enzyme medication by students diagnosed with pancreatic insufficiency or cystic fibrosis enrolled in the public school system.

    SUMMARY OF STATEMENT OF ESTIMATED REGULATORY COSTS AND LEGISLATIVE RATIFICATION:

    The Agency has determined that this will not have an adverse impact on small business or likely increase directly or indirectly regulatory costs in excess of $200,000 in the aggregate within one year after the implementation of the rule. A SERC has not been prepared by the Agency.

    The Agency has determined that the proposed rule is not expected to require legislative ratification based on the statement of estimated regulatory costs or if no SERC is required, the information expressly relied upon and described herein: The implementation of the rule will have no financial impact on the Department of Education as implementation will be done with existing resources. School districts may have some costs associated with additional training of staff but any costs are expected to be de minimus. The Agency has determined that the amended rule is not expected to require legislative ratification based on the statement of estimated regulatory costs.

    Any person who wishes to provide information regarding a statement of estimated regulatory costs, or provide a proposal for a lower cost regulatory alternative must do so in writing within 21 days of this notice.

    RULEMAKING AUTHORITY: 1001.02, 1002.20(3)(k) FS.

    LAW IMPLEMENTED: 1002.20(3)(k) FS.

    A HEARING WILL BE HELD AT THE DATE, TIME AND PLACE SHOWN BELOW:

    DATE AND TIME: June 17, 2014, 8:30 a.m.

    PLACE: Nassau County School Board, 1201 Atlantic Avenue, Fernandina Bch., FL 32034.

    THE PERSON TO BE CONTACTED REGARDING THE PROPOSED RULE IS: Monica Verra-Tirado, Chief, Bureau of Exceptional Education and Student Services, K-12 Public Schools, 325 West Gaines St., Room 614, Tallahassee, FL 32399, (850)245-0475

     

    THE FULL TEXT OF THE PROPOSED RULE IS:

     

    6A-6.0252 Use of Prescribed Pancreatic Enzyme Supplements.

    (1) Definitions.

    (a) No change.

    (b) Individualized Health Care Plan (IHP). An IHP is a written plan of care developed at the local level to outline the provision of student healthcare services intended to achieve specific student outcomes. The IHP is part of the nursing process that is detailed in the National Association of School Nurses Position Statement: Individualized Healthcare Plans, The Role of the School Nurse (2013 2008), as incorporated by reference in Rule 6A-6.0253, F.A.C., Diabetes Management. The IHP is developed by a registered nurse (RN) in collaboration with the family, student, student’s health care providers, and school personnel for the management of pancreatic insufficiency or cystic fibrosis while in school, participating in school-sponsored activities, and in transit to or from school or school-sponsored activities. The IHP is child-specific and includes a written format for nursing assessment (health status, risks, concerns, and strengths), nursing diagnoses, interventions, delegation, training, expected outcomes, and goals to meet the health care needs of a student with pancreatic insufficiency or cystic fibrosis and to protect the safety of all students from the misuse or abuse of medication.

    (c) through (2) No change.

    Rulemaking Authority 1002.20(3)(k) FS. Law Implemented 1002.20(3)(k), 1006.062(4) FS. History–New 5-5-13, Amended_________.

     

    NAME OF PERSON ORIGINATING PROPOSED RULE: Mary Jane Tappen, Deputy Chancellor of Curriculum, Instruction and Student Services

    NAME OF AGENCY HEAD WHO APPROVED THE PROPOSED RULE: Pam Stewart, Commissioner, Department of Education

    DATE PROPOSED RULE APPROVED BY AGENCY HEAD: May 16, 2014

    DATE NOTICE OF PROPOSED RULE DEVELOPMENT PUBLISHED IN FAR: April 8, 2014

Document Information

Comments Open:
5/20/2014
Summary:
The rule is amended because the National Association of School Nurses Position Statement was updated in June 2013. This rule was developed in cooperation with the Florida Department of Health (FDOH) to address self-administration of pancreatic enzyme medication by students diagnosed with pancreatic insufficiency or cystic fibrosis enrolled in the public school system.
Purpose:
The purpose and effect of this rule amendment is to update the rule to reflect the new position statement by the National Association of School Nurses incorporated by reference rule 6A-6.0253, FAC.
Rulemaking Authority:
1001.02, 1002.20(3)(k), F.S.
Law:
1002.20(3)(k), F.S.
Contact:
Monica Verra-Tirado, Chief, Bureau of Exceptional Education and Student Services, K-12 Public Schools, 325 West Gaines St., Room 614, Tallahassee, FL 32399, (850)245-0475.
Related Rules: (1)
6A-6.0252. Use of Prescribed Pancreatic Enzyme Supplements